Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Return on Equity (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Return on Equity for 4 consecutive years, with 0.29% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity rose 36.0% year-over-year to 0.29%, compared with a TTM value of 0.29% through Sep 2025, up 36.0%, and an annual FY2024 reading of 1.01%, up 501.0% over the prior year.
  • Return on Equity was 0.29% for Q3 2025 at Summit Therapeutics, up from 0.42% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.13% in Q4 2022 and bottomed at 6.89% in Q4 2023.
  • Average Return on Equity over 4 years is 2.07%, with a median of 0.65% recorded in 2024.
  • The sharpest move saw Return on Equity plummeted -676bps in 2023, then skyrocketed 632bps in 2024.
  • Year by year, Return on Equity stood at 0.13% in 2022, then tumbled by -5182bps to 6.89% in 2023, then soared by 92bps to 0.57% in 2024, then skyrocketed by 49bps to 0.29% in 2025.
  • Business Quant data shows Return on Equity for SMMT at 0.29% in Q3 2025, 0.42% in Q2 2025, and 0.52% in Q1 2025.